WELCOME to: 'Stu's Views and MS News' an informational archive

· Key-Note: This blog provides information and resources to benefit those affected by Multiple Sclerosis.

· Our live MS educational seminars average 67 people per educational program. SINCE our first program in February 2010, we have hosted more than 130 educational programs.

· Register at our website (MS Views and News) to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries. Visit MS Views and News.org

· WATCH OUR Multiple Sclerosis archived MS EDUCATIONAL VIDEOS by Topic. Click: www.youtube.com/msviewsandnews

Be Empowered with Beneficial MS Information

Scroll to view all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specific information.

===================================================================

Thursday, October 1, 2009

A major unmet need in the treatment of Multiple Sclerosis is a medication to increase walking ability.

A major unmet need in the treatment of Multiple Sclerosis is a medication to increase walking ability. Since disease modifying therapies have only been available for 16 years, MS starts at a mean age of 29, and the disease has only a minimal effect at shortening lifespan, the majority of MS patients presently have progressive forms of MS. Ten percent have primary progressive disease, progressive from the onset, and others, start with relapsing remitting MS, and progress after approximately 15 years to progressive illness. In the early years of progressive MS, patients loose the ability to walk, hence the prior motto of the National MS Society, "MS, the great crippler of young adults."

FAMPRIDINE-SR IS THE FIRST MEDICATION FOUND TO IMPROVE MS PATIENTS ABILITY TO WALK. Standard disease modifying agents, the interferons (Avonex, Betaseron, Rebif), Copaxone and Tysabri, decrease relapse rate and may slow progression, however do not improve one's ability to walk.



============================================

No comments: